Roche sees a slight dip in Q1 as biosimilars keep biting into blockbuster oncology trio’s sales

With Roche facing a fast decline for its oncology blockbuster trio amid a biosimilar onslaught, the drug giant is looking anywhere it can for a pick-me-up. That boost could come from Covid-19 diagnostics, the drugmaker said in a first-quarter update — but will it be enough?

The testing division saw...

Click to view original post